Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 9/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1381502 | 1.00 | KCNA5 (0.66) | KCNA5KCNH2ADORA1EGLN2EGLN1 | |
| SCHEMBL6047738 | 1.00 | KCNA5 (0.66) | KCNA5KCNH2ADORA1EGLN2EGLN1 | |
| SCHEMBL1384017 | 0.90 | KCNA5 (0.81) | KCNA5KCNH2ADORA1EGLN2EGLN1 | |
| SCHEMBL5500034 | 0.90 | KCNA5 (0.81) | KCNA5KCNH2ADORA1EGLN2EGLN1 | |
| SCHEMBL1385728 | 0.90 | KCNA5 (0.81) | KCNA5KCNH2ADORA1EGLN2EGLN1 | |
| SCHEMBL3122262 | 0.83 | KCNA5 (0.66) | KCNA5KCNH2ADORA1EGLN2EGLN1 | |
| SCHEMBL6047723 | 0.83 | KCNA5 (0.66) | KCNA5KCNH2ADORA1EGLN2EGLN1 | |
| SCHEMBL3122268 | 0.83 | KCNA5 (0.66) | KCNA5KCNH2ADORA1EGLN2EGLN1 | |
| SCHEMBL1382989 | 0.82 | KCNA5 (0.68) | KCNA5KCNH2EGLN2EGLN1L3MBTL1 | |
| SCHEMBL1383316 | 0.82 | KCNA5 (0.68) | KCNA5KCNH2EGLN2EGLN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691879-B2 | Isoquinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-04-06 | — | — | US | claimed |
| US-7691879-B2 | Isoquinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691879-B2 | Isoquinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691879-B2 | Isoquinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20060276450-A1 | Isoquinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276450-A1 | Isoquinoline potassium channel inhibitors | KCNQ1, KCNQ2, KCNJ2 | KCNA5 15/4885KCNH2 5/4885ADORA1 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.